Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + IMRT for HCC with PVTT
NCT04850157Phase 2Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Apr 2021
- Primary completion
- Apr 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in hepatocellular carcinoma (HCC), sponsored by Zhongshan Hospital, Fudan University. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04850157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04850157.